EyePoint Pharmaceuticals, Inc.
EYPT
$5.55
-$0.12-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.97% | 7.50% | 34.98% | 25.70% | 11.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.97% | 7.50% | 34.98% | 25.70% | 11.14% |
| Cost of Revenue | 34.13% | -54.33% | -71.37% | -80.75% | -108.56% |
| Gross Profit | -8.71% | 268.23% | 415.52% | 283.74% | 407.83% |
| SG&A Expenses | 4.41% | -2.94% | -14.24% | -13.54% | -12.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.19% | 30.91% | 21.07% | 12.18% | 0.62% |
| Operating Income | -94.30% | -43.08% | -15.01% | -5.63% | 4.90% |
| Income Before Tax | -84.95% | -3.33% | 18.14% | 23.05% | 30.85% |
| Income Tax Expenses | 8.43% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.86% | -3.42% | 18.06% | 22.97% | 30.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.86% | -3.42% | 18.06% | 22.97% | 30.77% |
| EBIT | -94.30% | -43.08% | -15.01% | -5.63% | 4.90% |
| EBITDA | -93.44% | -42.83% | -15.70% | -7.25% | 2.46% |
| EPS Basic | -25.87% | 24.76% | 36.56% | 33.36% | 32.92% |
| Normalized Basic EPS | -28.44% | 3.49% | 19.95% | 18.21% | 16.03% |
| EPS Diluted | -25.87% | 24.76% | 36.56% | 33.36% | 32.92% |
| Normalized Diluted EPS | -28.44% | 3.49% | 19.95% | 18.21% | 16.03% |
| Average Basic Shares Outstanding | 44.71% | 34.48% | 24.62% | 14.38% | 4.22% |
| Average Diluted Shares Outstanding | 44.71% | 34.48% | 24.62% | 14.38% | 4.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |